Zobrazeno 1 - 10
of 39
pro vyhledávání: '"J Spertino"'
Autor:
C Socias Cañellas, P Riera, M Masip, E Serra-Baldrich, J Spertino, E Roé-Crespo, N Pagès-Puigdemont
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dac3614514a882d202a2ce1d77ce1496
https://doi.org/10.1136/ejhpharm-2023-eahp.312
https://doi.org/10.1136/ejhpharm-2023-eahp.312
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Actas Dermo-Sifiliográficas. 110:289-296
Resumen Antecedentes Aunque la eficacia del omalizumab en el tratamiento de la urticaria cronica espontanea esta demostrada en ensayos clinicos de fase iii , la informacion disponible sobre la efectividad en la vida real utilizando la puntuacion de a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b856d7495fb31dc79edfcd1e94dd3156
https://doi.org/10.1016/j.ad.2018.09.009
https://doi.org/10.1016/j.ad.2018.09.009
Publikováno v:
Actas Dermo-Sifiliográficas (English Edition). 110:289-296
Background The efficacy of omalizumab in the treatment of chronic spontaneous urticaria has been demonstrated in phase iii clinical trials, but limited information is available regarding real-life effectiveness using the weekly Urticarial Activity Sc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::013463e97fea4827fb58211af4ee8415
https://doi.org/10.1016/j.adengl.2018.09.015
https://doi.org/10.1016/j.adengl.2018.09.015
Autor:
E Serra-Baldrich, Xavier García-Navarro, Antonio Guilabert, Gemma Melé-Ninot, Vicente Expósito-Serrano, Ignasi Figueras-Nart, J. Spertino, Isabel Bielsa-Marsol, Laia Curto-Barredo, Ana Giménez-Arnau
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 16, p adv00267 (2020)
is missing (Short communication)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c651aadae11ad97539437d49acd3efb
https://pubmed.ncbi.nlm.nih.gov/32926176
https://pubmed.ncbi.nlm.nih.gov/32926176
Autor:
J. Spertino, L. Curto Barredo, E. Rozas Muñoz, I. Figueras Nart, A. Gimenez Arnau, E. Serra Baldrich, M. Bonfill-Ortí, V. Expósito-Serrano, A. Guilabert, G. Melé Ninot, M. Villar Buil, J. Garcias Ladaria, X. García Navarro, M. Vilavella, I. Bielsa Marsol, G. Aparicio Ortiz, C. Baliu Piqué, A. Álvarez Abella, N. Lamas Domenech, J.M. Mascaró, S. Gómez, J.I. Torné Gutiérrez, A. Vicente Villa
Publikováno v:
Actas Dermo-Sifiliográficas. 109:771-776
Resumen Antecedentes y objetivo Los ensayos pivotales de omalizumab en urticaria cronica espontanea (UCE) tienen un periodo de tratamiento de entre 12 y 24 semanas. Sin embargo, muchos pacientes en practica clinica requieren periodos de tratamiento m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d71ef63dcbf9e61f950706aae47e6666
https://doi.org/10.1016/j.ad.2018.07.005
https://doi.org/10.1016/j.ad.2018.07.005
Autor:
Ana Giménez-Arnau, S. Gómez Armayones, N. Fernández Chico, Gemma Melé-Ninot, I. Figueras Nart, A. Sala Cunill, Moises Labrador-Horrillo, A. Guilabert Vidal, J. Spertino, E Serra-Baldrich, P. Aguilera Peiro, Laia Curto-Barredo, C. Baliu-Piqué, V. Expósito-Serrano, M. Bonfill Ortí
Publikováno v:
British Journal of Dermatology. 184:167-168
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c946f32a139803395a2b1f79daa6a43b
https://doi.org/10.1111/bjd.19425
https://doi.org/10.1111/bjd.19425
Autor:
J Spertino, S Alcantara Luna, Ana Giménez-Arnau, Ramon M. Pujol, V Zaragoza Ninet, Gustavo Deza, I Ogueta
Publikováno v:
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77612b0f04ef6d248e592209e3807d04
http://repositori.upf.edu/bitstream/10230/43722/1/ogueta-jea-well.pdf
http://repositori.upf.edu/bitstream/10230/43722/1/ogueta-jea-well.pdf
Publikováno v:
Actas dermo-sifiliograficas. 110(4)
The efficacy of omalizumab in the treatment of chronic spontaneous urticaria has been demonstrated in phase iii clinical trials, but limited information is available regarding real-life effectiveness using the weekly Urticarial Activity Score (UAS7).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dfe6b80d9a21f6950342a8ee330103b8
https://pubmed.ncbi.nlm.nih.gov/30879603
https://pubmed.ncbi.nlm.nih.gov/30879603
Autor:
J, Spertino, L, Curto Barredo, E, Rozas Muñoz, I, Figueras Nart, A, Gimenez Arnau, E, Serra Baldrich, M, Bonfill-Ortí, V, Expósito-Serrano, A, Guilabert, G, Melé Ninot, M, Villar Buil, J, Garcias Ladaria, X, García Navarro, M, Vilavella, I, Bielsa Marsol, G, Aparicio Ortiz, C, Baliu Piqué, A, Álvarez Abella, N, Lamas Domenech, J M, Mascaró, S, Gómez, J I, Torné Gutiérrez, A, Vicente Villa
Publikováno v:
Actas dermo-sifiliograficas. 109(9)
Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d9a9d4b908f21b92e91fbab6a2465918
https://pubmed.ncbi.nlm.nih.gov/30107875
https://pubmed.ncbi.nlm.nih.gov/30107875